Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with fulvestrant for endocrine-resistant HR-positive/HER2-negative advanced breast cancer
ChiCTR2100044282Phase 4Recruiting
- Sponsor
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat and fulvestrant in breast cancer, sponsored by Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment. Primary endpoint: Progression-free survival. Started Mar 2021; status: recruiting.
02
Drugs
tucidinostatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100044282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044282.